This double-blind, placebo-controlled clinical study will evaluate ritanserin and two manually-guided therapies in the treatment of cocaine dependence. Cocaine dependent patients (N = 198) completing a 14-day inpatient treatment program will be randomly assigned to one of six treatment cells in a 3 X 2 factorial design comparing drug group (placebo, 5 mg, 10 mg) and psychotherapy (relapse prevention, standard drug counseling). The 12-week outpatient treatment will involve twice weekly individual psychotherapy contacts. Relapse prevention techniques will emphasize coping skills training, handling drug use episodes, and general lifestyle changes to maintain abstinence. Standard drug counseling will be nondirective and supportive. Drug history, addiction severity, psychosocial functioning, and coping skills will be measured at pretreatment. During treatment, biweekly urinalysis testing will bs conducted, along with weekly measurement of cocaine craving, side effects, and mood state. Short-term outcome will be assessed at treatment termination, followed by repeated assessments over a 1-year period to examine treatment durability. Primary dependent variables will include cocaine use (urine screen and self-report), treatment attendance, retention rates, and medication compliance. Drug use outcomes will be analyzed according to: (a) proportion of cocaine- positive urine drug screens; (b) duration of continuous periods of abstinence; (c) cocaine craving ratings; (d) rates of relapse to other illicit drugs. Other indices of treatment improvement will include: (a) ASI ratings of problem severity; (b) coping scores on the Situational Competency Test; (c) psychosocial functioning (i.e., depression, social support, perceived stress). We predict that ritanserin will be superior to placebo on outcome measures related to cocaine consumption. Furthermore, type of therapy will interact with the effect of medication on most outcome measures. Specifically, subjects receiving ritanserin and relapse prevention therapy will be less likely to experience a relapse to regular cocaine use and will report better short- and long-term psychosocial functioning compared to subjects in the control groups. Finally, this project will establish a joint pharmacotherapy- psychotherapy model to support research on medications development for cocaine dependence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009262-05
Application #
6270036
Study Section
Project Start
1998-08-01
Project End
1999-09-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
City
Houston
State
TX
Country
United States
Zip Code
77225
D'Souza MA, Johann M; Wardle PhD, Margaret; Green PhD, Charles E et al. (2018) Resting Heart Rate Variability: Exploring Associations With Symptom Severity in Adults With Substance Use Disorders and Posttraumatic Stress. J Dual Diagn :1-6
Vujanovic, Anka A; Wardle, Margaret C; Bakhshaie, Jafar et al. (2018) Distress tolerance: Associations with trauma and substance cue reactivity in low-income, inner-city adults with substance use disorders and posttraumatic stress. Psychol Addict Behav 32:264-276
Miller, William R; Fox, Robert G; Stutz, Sonja J et al. (2018) PPAR? agonism attenuates cocaine cue reactivity. Addict Biol 23:55-68
Vujanovic, Anka A; Smith, Lia J; Green, Charles E et al. (2018) Development of a novel, integrated cognitive-behavioral therapy for co-occurring posttraumatic stress and substance use disorders: A pilot randomized clinical trial. Contemp Clin Trials 65:123-129
Ma, Liangsuo; Steinberg, Joel L; Wang, Qin et al. (2017) A preliminary longitudinal study of white matter alteration in cocaine use disorder subjects. Drug Alcohol Depend 173:39-46
Schmitz, Joy M; Green, Charles E; Hasan, Khader M et al. (2017) PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a double-blind randomized controlled pilot trial. Addiction 112:1861-1868
Wardle, Margaret C; Vincent, Jessica N; Suchting, Robert et al. (2017) Anhedonia Is Associated with Poorer Outcomes in Contingency Management for Cocaine Use Disorder. J Subst Abuse Treat 72:32-39
Ahn, Woo-Young; Ramesh, Divya; Moeller, Frederick Gerard et al. (2016) Utility of Machine-Learning Approaches to Identify Behavioral Markers for Substance Use Disorders: Impulsivity Dimensions as Predictors of Current Cocaine Dependence. Front Psychiatry 7:34
Azadeh, Shabnam; Hobbs, Brian P; Ma, Liangsuo et al. (2016) Integrative Bayesian analysis of neuroimaging-genetic data with application to cocaine dependence. Neuroimage 125:813-824
Sharma, Jyoti; Rathnayaka, Nuvan; Green, Charles et al. (2016) Bradycardia as a Marker of Chronic Cocaine Use: A Novel Cardiovascular Finding. Behav Med 42:1-8

Showing the most recent 10 out of 88 publications